As we known, a few studies have targeted therapy in elder with chronic HCV. Aim: We reviewed the results of interferon based antiviral therapy in the elderly with chronic HCV at our institution. Methods: Patients were defined as elderly if they were 65 years and elder who received therapy for HCV. The prescribed treatment duration, end of treatment response were mention. The data recorded included laboratory tests, adverse events (AE), dose modification, and withdrawal rate of therapy. Results: 304 of chronic HCV patients treated with peg-IFN/ribavirin between Nov 2004 and Feb 2008. 50 patients were older than 65 years old. The mean age of the elder patients was 70.3 ± 4.8 years old. 21 were male and 29 were female. Histological studies showed 18 with cirrhosis. Almost all patients had experienced AE/side effects. The most common abnormalities were anemia and neutropenia. Therapy was discontinued in 22% (11/50). The rate of dose modification was 46% (18/39) patients who received 24 weeks therapy. Transaminases were normalized in 66% (33/50) after 24 weeks treatment and sustained in 66% (29/44) one year later. Conclusion: The elder patients are more at risk of developing AE while on treatment. Most patients should be discontinued or decreased dosage of medication. However, the elder patients with chronic HCV can be treated successfully. Background: In the general population the incidence of interstitial lung disease is estimated to be 0.03% and has also been reported with the use of interferons. The higher reporting rate of IP in Japan has created interest and warrants further investigation. Methods: Using both data from 12 randomized clinical trials (ex-Japan) and the Roche world-wide safety database (ADVENT), the frequency of IP was estimated in patients treated with peginterferon alfa-2a ± ribavirin. IP was defined as: interstitial lung disease, alveolitis, pulmonary fibrosis, pneumonitis and pulmonary toxicity. Results: One case of IP was reported among the 6180 patients included in the clinical trials (0.02%). In the ADVENT database considering the estimated 926,000 patients with cumulative exposure to peginterferon alfa-2a (42,600 in Japan and 883,400 US/ROW) the 228 reported cases of IP represent a rate of 0.02% with a proportional reporting ratio (PRR) of 1.7 (p<0.0001). Of these cases, 140 were reported in Japan (PRR 2.9; p<0.0001), 34 in the USA (PRR 0.7; p=0.06) and 54 ROW (PRR 1.2; p=0.11) representing reporting rates of 0.3% in Japan and 0.01% in the USA and ROW. Japanese patients with reported IP were older (66 versus 50-55 years) and were more likely to have been treated with peginterferon alfa-2a monotherapy (81% versus 21-39%). Furthermore, the yearly incidence rate has remained unchanged. Conclusions: The apparently higher rate of IP reported in Japan may result from differences in patient demography, diagnostic criteria and treatment patterns. The overall incidence of IP remains low. Background: Hepatitis C virus (HCV) infection carries a significant risk for development of insulin resistance (IR) and/or diabetes (DM). Recently, retinol-binding protein 4 (RBP4) has been reported as a protein contributing to IR. This study aimed to assess the different expression of serum RBP4 between chronic HCV infection (CHC) patients and non-CHC controls. Methods: Serum RBP4 was measured in 105 treatment-naïve CHC patients and its correlation with the homeostasis model assessment of insulin resistance index (HOMA-IR), liver histology, virology and metabolic factors was investigated. Patients were stratified into different stages of glucose tolerance by oral glucose tolerance test. Another 100 sex-and age-matched non-CHC adults served as the controls. Results: The mean RBP4 level of controls tended to be higher than that of CHC patients (32.46 ± 20.92 vs 25.48 ± 13.13 g/mL, P=0.07). The mean RBP4 level of 34 IGT control-group subjects was 43.7 ± 24.0 g/mL, which was significantly higher than that of 34 NGT (24.4 ± 13.0 g/mL, P<0.001) and 32 DM controls (29.0 ± 19.5 g/mL, P<0.01). In contrast, the mean RBP4 level (22.2 ± 10.3 g/mL) of 32 DM/CHC patients was not significantly different from that of NGT/CHC (24.9 ± 10.5 g/mL, n=28) and IGT /CHC (28.1 ± 15.8 g/mL, n=45) patients. Amongst CHC patients, there was a significant decreasing linear trend of RBP4 dependent of both histological grading and staging progression, whilst a significant increment of HOMA-IR was found. Conclusion: Serum RBP4 is dysregulated in CHC patients. Introduction: Sustained Viral Response (SVR) in Hepatitis C treatment with Interferon Alfa and Ribavirin is affected by adherence and compliance due to severe myalgia, fatigue-anxiety and disturbed sleep. Pregabalin, an orally effective GABAsergic drug is not metabolized via Cytochrome P450 and is used in fibromyalgia and fatigue-anxiety syndromes without hepatic toxicity.This study evaluates the addition of Pregablin to standard agents in achieving SVR by reducing side events. Methods: Thirty patients with chronic hepatitis C {mean age -46 years, male: female -2:1,Genotype(G)1(n=29), G6 (n=1), Fibrotic score F2-3 (n=24) and F4 (n=6), mean BMI > 29 Kg/m 2 , initial viral load > 800,000 IU/ml} were randomized to Pregablin100mg (n=15) or Duloxetine 20mg (n=15) both orally daily with Interferon Alfa 2a 180mcg sq once a week and Ribavirin 1200mg daily for 48 weeks. Myalgia anxiety scale, modified quality of life score -evaluated at entry and tri-monthly. All were tested for rapid viral response, early viral response and end treatment viral response and SVR.